Objective Response Rate (ORR) in the liver was a secondary endpoint of the SIRFLOX study. SIR-Spheres® Y-90 resin microspheres in combination with first line chemotherapy, versus chemotherapy alone, showed a significant increase of 9.9% in ORR in the liver and a three-fold improvement in complete response rate (CR) in the liver.1
Patients who had a smaller liver tumour burden (≤12%) on study entry were more than six times as likely to experience a complete response or disappearance of all liver tumours following SIR-Spheres Y-90 resin microspheres compared to those who received only chemotherapy (11.3% vs.1.7%; p=0.003).2
bev*: bevacizumab (bevacizumab allowed at investigator’s discretion, per institutional practice)
No statistically significant improvement of PFS at any site
1. van Hazel GA et al. J Clin Oncol 2016; 34: 1723–1731.
2. Heinemann V et al. ESMO WCGIC, Annals of Oncology 2016; 27 (Suppl 2): Abs. O-014.